ME02938B - Fluorirani antagonisti integrina - Google Patents
Fluorirani antagonisti integrinaInfo
- Publication number
- ME02938B ME02938B MEP-2017-281A MEP2017281A ME02938B ME 02938 B ME02938 B ME 02938B ME P2017281 A MEP2017281 A ME P2017281A ME 02938 B ME02938 B ME 02938B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound according
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Jedinjenje formule I: ili njegova farmaceutski prihvatljiva so ili solvat, naznačeno time, da: Z je R i R' su svaki nezavisno H ili F, ili R i R', zajedno sa ugljenikovim atomom na koji su vezani, formiraju 3 ili 4-člani karbociklični ili heterociklični prsten; Q je X je CH ili N; Y je CH ili N; R1 je metoksi supstituisan sa 0, 1, 2, ili 3 atoma fluora; i pod uslovom da jedinjenje formule (I) sadrži najmanje jedan atom fluora.
2. Jedinjenje prema patentnom zahtjevu 1, naznačeno time, da R i R’su svaki H.
3. Jedinjenje prema patentnom zahtjevu 1, naznačeno time, da X je N i Y je CH.
4. Jedinjenje prema patentnom zahtjevu 1, naznačeno time, da X i Y su svaki CH.
5. Jedinjenje prema patentnom zahtjevu 1, naznačeno time, da X i Y su svaki N.
6. Jedinjenje prema patentnom zahtjevu 1, naznačeno time, da R1 je OCHF2.
7. Jedinjenje prema patentnom zahtjevu 1, koje ima formulu II: ili njegova farmaceutski prihvatljiva so ili solvat.
8. Jedinjenje prema patentnom zahtjevu 1, odabrano iz grupe koja se sastoji od: i ili njegova farmaceutski prihvatljiva so ili solvat.
9. Jedinjenje prema patentnom zahtjevu 8, gde je jedinjenje ili njegova farmaceutski prihvatljiva so ili solvat.
10. Farmaceutski preparat, koji sadrži jedinjenje prema bilo kom od prethodnih patentnih zahtjeva ili njegovu farmaceutski prihvatljivu so ili solvat, i farmaceutski prihvatljiv nosač ili ekscipijens, naznačen time, da farmaceutski preparat opciono dalje sadrži aktivni sastojak izabran iz grupe koja se sastoji od a) antagoniste integrina α5β1, b) citotoksičnog / antiproliferativnog agensa, c) inhibitora faktora rasta izvedenog iz epiderma, izvedenog iz fibroblasta, ili izvedenog iz trombocita, d) inhibitora VEGF, e) inhibitora Flk-1/KDR, Flt-1, Tck/Tie-2 ili Tic-1, i f) inhibitora fosfoinozitid 3-kinaze i njihove mešavine.
11. Jedinjenje prema bilo kom od patentnih zahtjeva 1 do 9 ili njegova farmaceutski prihvatljiva so ili solvat, opciono u kombinaciji sa jednom ili više terapija, ili preparat prema patentnom zahtevu 10, za upotrebu u postupku lečenja ili prevencije bolesti ili stanja posredovanog αv integrinom kod subjekta.
<!--[if !supportLists]-->1. <!--[endif]--> Jedinjenje ili preparat za upotrebu prema patentnom zahtjevu 11, naznačen time, da je bolest ili stanje odabrano iz grupe koja se sastoji od makularne degeneracije, dijabetične retinopatije (DR), makularnog edema, dijabetičnog makularnog edema (DME) i makularnog edema nakon okluzije retinalne vene (RVO).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762087P | 2013-02-07 | 2013-02-07 | |
| US201361900706P | 2013-11-06 | 2013-11-06 | |
| PCT/US2014/015372 WO2014124302A1 (en) | 2013-02-07 | 2014-02-07 | Fluorinated integrin antagonists |
| EP14749249.0A EP2953948B1 (en) | 2013-02-07 | 2014-02-07 | Fluorinated integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02938B true ME02938B (me) | 2018-04-20 |
Family
ID=51300167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-281A ME02938B (me) | 2013-02-07 | 2014-02-07 | Fluorirani antagonisti integrina |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US9518053B2 (me) |
| EP (3) | EP2953948B1 (me) |
| JP (2) | JP6494528B2 (me) |
| KR (1) | KR102216091B1 (me) |
| CN (2) | CN105246889B (me) |
| AU (1) | AU2014214737B2 (me) |
| BR (2) | BR122019026750B1 (me) |
| CA (1) | CA2899321C (me) |
| CY (1) | CY1120213T1 (me) |
| DK (1) | DK2953948T3 (me) |
| ES (2) | ES2763556T3 (me) |
| HR (1) | HRP20171873T1 (me) |
| HU (1) | HUE035357T2 (me) |
| IL (2) | IL240181A (me) |
| LT (1) | LT2953948T (me) |
| ME (1) | ME02938B (me) |
| PL (1) | PL2953948T3 (me) |
| PT (1) | PT2953948T (me) |
| RS (1) | RS56711B1 (me) |
| RU (1) | RU2698195C2 (me) |
| SI (1) | SI2953948T1 (me) |
| SM (1) | SMT201700611T1 (me) |
| WO (1) | WO2014124302A1 (me) |
| ZA (1) | ZA201505575B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| ME02938B (me) * | 2013-02-07 | 2018-04-20 | Scifluor Life Sciences Inc | Fluorirani antagonisti integrina |
| ES2899860T3 (es) | 2013-09-24 | 2022-03-15 | Fujifilm Corp | Nuevo compuesto que contiene nitrógeno o sal del mismo, o complejo de metal de los mismos |
| WO2015175954A1 (en) * | 2014-05-16 | 2015-11-19 | Scifluor Life Sciences, Inc. | Alpha v integrin antagonist compositions |
| US9790222B2 (en) * | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| MX2017013880A (es) | 2015-04-30 | 2018-08-01 | Scifluor Life Sciences Inc | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| AU2017292754B2 (en) * | 2016-07-05 | 2021-06-17 | Icahn School Of Medicine At Mount Sinai | Tetrahydronaphthyridinepentanamide integrin antagonists |
| BR112019009245A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| RS61453B1 (sr) * | 2016-11-08 | 2021-03-31 | Bristol Myers Squibb Co | Amidi pirola kao inhibitori alfa v integrina |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| WO2021231581A1 (en) | 2020-05-12 | 2021-11-18 | Scifluor Life Sciences, Inc. | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS |
| WO2023230042A1 (en) * | 2022-05-23 | 2023-11-30 | Ocuterra Therapeutics, Inc. | Treating diabetic retinopathy using an integrin inhibitor |
| WO2024006248A1 (en) * | 2022-06-27 | 2024-01-04 | Ocuterra Therapeutics, Inc. | Stable ophthalmic formulations of a fluorinated integrin antagonist |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN116239665B (zh) * | 2023-03-10 | 2024-08-23 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| DK0581904T3 (da) | 1991-04-01 | 1997-12-29 | Univ Duke | Fremgangsmåde til inhibering af fibrose |
| US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US5736357A (en) | 1994-10-27 | 1998-04-07 | Arris Pharmaceutical | Cathespin O protease |
| US6544767B1 (en) | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US6211184B1 (en) | 1996-08-29 | 2001-04-03 | Merck & Co., Inc. | Integrin antagonists |
| AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO1999031061A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| ATE298338T1 (de) * | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrin-rezeptor-antagonisten |
| CN1284955A (zh) * | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| US6677360B2 (en) * | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| DE69927050T2 (de) * | 1998-12-16 | 2006-06-29 | Bayer Healthcare Ag | Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten |
| US6291503B1 (en) | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| ATE368462T1 (de) * | 1999-06-02 | 2007-08-15 | Merck & Co Inc | Alpha v integrin-rezeptor antagonisten |
| US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| EP1252162B1 (en) | 2000-01-20 | 2012-07-25 | Merck Sharp & Dohme Corp. | Alpha v integrin receptor antagonists |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| EP1192949A4 (en) | 2000-02-22 | 2005-11-09 | Daiichi Suntory Pharma Co Ltd | PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| AU2001277935B2 (en) * | 2000-07-26 | 2005-08-04 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| JP2004509123A (ja) | 2000-09-14 | 2004-03-25 | メルク エンド カムパニー インコーポレーテッド | アルファνインテグリン受容体アンタゴニスト |
| WO2002022124A1 (en) | 2000-09-18 | 2002-03-21 | Merck & Co., Inc. | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| EP1444231A4 (en) | 2001-11-06 | 2005-11-09 | Merck & Co Inc | AMINO SALT OF AN INTEGRIN RECEPTOR ANTAGONIST |
| US20040053968A1 (en) * | 2001-12-28 | 2004-03-18 | Hartman George D. | Methods and compositions for treating peridontal disease |
| AU2003267216A1 (en) * | 2002-09-20 | 2004-04-08 | Merck & Co., Inc. | Mannitol formulation for integrin receptor antagonist |
| CA2507699A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| CA2540730C (en) | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| WO2011060395A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Cyclic ureas useful as hiv inhibitors |
| MX351368B (es) | 2010-05-26 | 2017-10-12 | Sunovion Pharmaceuticals Inc | Compuestos heteroarilo y metodos para utilizarlos. |
| KR102165421B1 (ko) | 2011-05-09 | 2020-10-14 | 알레그로 파마슈티칼스, 인코포레이티드. | 인테그린 수용체 길항물질 및 이의 사용 방법 |
| EP2726057A1 (en) | 2011-06-28 | 2014-05-07 | Bayer HealthCare LLC | Topical ophthalmological pharmaceutical composition containing sorafenib |
| ME02938B (me) * | 2013-02-07 | 2018-04-20 | Scifluor Life Sciences Inc | Fluorirani antagonisti integrina |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| MX2017013880A (es) | 2015-04-30 | 2018-08-01 | Scifluor Life Sciences Inc | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. |
| WO2018183795A1 (en) | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
-
2014
- 2014-02-07 ME MEP-2017-281A patent/ME02938B/me unknown
- 2014-02-07 HR HRP20171873TT patent/HRP20171873T1/hr unknown
- 2014-02-07 HU HUE14749249A patent/HUE035357T2/en unknown
- 2014-02-07 EP EP14749249.0A patent/EP2953948B1/en active Active
- 2014-02-07 PT PT147492490T patent/PT2953948T/pt unknown
- 2014-02-07 WO PCT/US2014/015372 patent/WO2014124302A1/en not_active Ceased
- 2014-02-07 DK DK14749249.0T patent/DK2953948T3/en active
- 2014-02-07 BR BR122019026750-2A patent/BR122019026750B1/pt active IP Right Grant
- 2014-02-07 ES ES17186012T patent/ES2763556T3/es active Active
- 2014-02-07 JP JP2015557136A patent/JP6494528B2/ja not_active Expired - Fee Related
- 2014-02-07 CA CA2899321A patent/CA2899321C/en active Active
- 2014-02-07 RU RU2015137785A patent/RU2698195C2/ru active
- 2014-02-07 SM SM20170611T patent/SMT201700611T1/it unknown
- 2014-02-07 CN CN201480020172.3A patent/CN105246889B/zh active Active
- 2014-02-07 KR KR1020157022414A patent/KR102216091B1/ko not_active Expired - Fee Related
- 2014-02-07 RS RS20171250A patent/RS56711B1/sr unknown
- 2014-02-07 ES ES14749249.0T patent/ES2651162T3/es active Active
- 2014-02-07 BR BR112015019039-1A patent/BR112015019039B1/pt active IP Right Grant
- 2014-02-07 PL PL14749249T patent/PL2953948T3/pl unknown
- 2014-02-07 EP EP19205757.8A patent/EP3674301A1/en not_active Withdrawn
- 2014-02-07 EP EP17186012.5A patent/EP3266782B1/en active Active
- 2014-02-07 SI SI201430481T patent/SI2953948T1/en unknown
- 2014-02-07 AU AU2014214737A patent/AU2014214737B2/en not_active Ceased
- 2014-02-07 CN CN201810749035.3A patent/CN108690022B/zh active Active
- 2014-02-07 US US14/766,322 patent/US9518053B2/en active Active
- 2014-02-07 LT LTEP14749249.0T patent/LT2953948T/lt unknown
-
2015
- 2015-07-28 IL IL240181A patent/IL240181A/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05575A patent/ZA201505575B/en unknown
-
2016
- 2016-05-04 IL IL245471A patent/IL245471B/en active IP Right Grant
- 2016-11-04 US US15/343,823 patent/US9717729B2/en not_active Expired - Fee Related
-
2017
- 2017-06-27 US US15/633,946 patent/US10106537B2/en active Active
- 2017-11-29 CY CY20171101252T patent/CY1120213T1/el unknown
-
2019
- 2019-03-05 JP JP2019039410A patent/JP2019108377A/ja active Pending
- 2019-05-13 US US16/409,960 patent/US20190263810A1/en not_active Abandoned
-
2020
- 2020-08-12 US US16/991,138 patent/US11685737B2/en active Active
-
2023
- 2023-06-21 US US18/212,324 patent/US12497399B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02938B (me) | Fluorirani antagonisti integrina | |
| ME02400B (me) | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| AR100171A1 (es) | Compuestos de diaminotriazina y su uso como herbicida | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| RU2017132433A (ru) | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение | |
| HRP20220502T1 (hr) | Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om | |
| HRP20171078T1 (hr) | Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| JP2016519078A5 (me) | ||
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| HRP20231563T1 (hr) | 4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe | |
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| BR112016007078A2 (pt) | composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |